syva PRESS RELEASE

# VMD grants marketing authorisation for Syvazul® BTV3 in United Kingdom

## Syvazul® BTV 3 has been granted a marketing authorisation in United Kingdom for use in cattle and sheep, with a reduced dose in cattle.

**León, 4 July 2025** – Syva is pleased to announce that **Syvazul® BTV 3 has been granted a marketing authorisation (Vm 31592/5006) in UK**, allowing its use **in cattle and sheep** to combat **Bluetongue virus serotype 3 (BTV-3)**. The authorisation, effective from **3 July 2025**, is **valid indefinitely**.

---

### A major update for cattle: reduced dose

A key breakthrough in this new authorisation is that **the dose for cattle has been reduced from 4 ml to 2 ml**, improving convenience and aligning with the latest regulatory data.

### Reminder Indications and administration

**-> Cattle**

- For active immunisation to reduce viraemia caused by BTV-3.
- **Onset of immunity**: 3 weeks after completing the primary vaccination course.

Dosage (intramuscular):

- From 2 months of age in naïve animals, or from 3 months if born to immune dams.
- **Primary vaccination**: 2 doses of 2 ml, 3 weeks apart.

**-> Sheep**

- For active immunisation to reduce viraemia, mortality, clinical signs and lesions caused by BTV-3.
- Onset of immunity: 4 weeks after completing the primary vaccination course.

Dosage (subcutaneous):

- From 3 months of age.
- **Primary vaccination**: 1 single dose of 2 ml.